La Jolla Pharmaceutical Company Announces Completion of Enrollment of Phase 2 Extension Study of GCS-100 in Chronic Kidney Disease

05-06-2014 Business Wire HealthComments (0)

La Jolla PharmaceuticalPharmaceuticalUSA

La Jolla Pharmaceutical completes enrollment of Phase 2 Extension Study of GCS-100 in chronic kidney disease

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top